Reasons to Retain TNDM Stock in Your Portfolio for Now
The renowned medical device company has a market capitalization of $2.31 billion. Tandem Diabetes projects a growth rate of 28.6% for 2025 earnings compared with 18.7% for the S&P 500. TNDM delivered ...
The Associated Press on MSN11d
Newsom committed California to making its own insulin. It’s at least a year behind his schedule
In a bid to bring down the cost of insulin, California under Gov. Gavin Newsom inked a contract to produce the drug. It's ...
Nasdaq6d
Reasons to Retain TNDM Stock in Your Portfolio for Now
Tandem Diabetes Care, Inc.’s TNDM impressive strategic initiatives are expected to bolster growth in the upcoming quarters. A robust diabetes market provides a favorable opportunity for the ...
Everyday Health12d
Over-the-Counter (OTC) Insulin: What You Need to Know
While this option may be less expensive and seems convenient, it’s best to consult a doctor about dosage if you use it, says Joshua J. Neumiller, CDCES, PharmD, the president elect of ...
Connecticut Post12d
Newsom committed California to making its own insulin. It’s at least a year behind his schedule
Gov. Gavin Newsom’s ambitious plan to produce a cheap, generic insulin for the 3.2 million Californians with diabetes is behind the schedule he announced and unlikely to make it to market for ...
Capital Public Radio11d
Newsom committed California to making its own insulin. It’s at least a year behind his schedule
Welcome to CalMatters, the only nonprofit newsroom devoted solely to covering issues that affect all Californians. Sign up for WhatMatters to receive the latest news and commentary on the most ...
Palo Alto Weekly12d
Newsom committed California to making its own insulin. It’s at least a year behind his schedule
Click to share on X (Opens in new window) Click to share on Facebook (Opens in new window) Click to print (Opens in new window) Click to email a link to a friend (Opens in new window) Gov.
Medscape1d
Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
The algorithm (Fig. 2) takes into account the characteristics of the individual interventions, their synergies, and expense. The goal is to achieve and maintain glycemic levels as close to the ...
pharmaphorum4d
Sanofi turns the tables on Lilly with biosimilar fast-acting insulin
Eli Lilly’s big-selling insulin, Humalog, faces cut-price competition after the US regulator approved a biosimilar from Sanofi. Sanofi’s Admelog (insulin lispro) is approved in type 1 and type ...